Published in Gan To Kagaku Ryoho on September 01, 2005
Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2012) 9.88
Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet (2002) 1.43
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis (2011) 1.39
Initial operative experience of single-port retroperitoneal laparoscopic nephrectomy. Int J Urol (2012) 1.39
Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. J Urol (2009) 1.15
Amino acid transporter LAT3 is required for podocyte development and function. J Am Soc Nephrol (2009) 1.06
Disease-causing missense mutations in NPHS2 gene alter normal nephrin trafficking to the plasma membrane. Kidney Int (2004) 1.04
Immunomagnetic quantification of circulating tumor cells in patients with urothelial cancer. Int J Urol (2010) 0.97
Laparoscopic management of urachal remnants in adulthood. Int J Urol (2006) 0.96
Role of amino acid transporter LAT2 in the activation of mTORC1 pathway and the pathogenesis of crescentic glomerulonephritis. Lab Invest (2011) 0.94
Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract (2005) 0.94
Prostatic cyst arising around the bladder neck-cause of bladder outlet obstruction: two case reports. Hinyokika Kiyo (2007) 0.92
[Comparison of clinical results between TUR-P and holmium laser enucleation of the prostate (HoLEP) based on the initial experience]. Nihon Hinyokika Gakkai Zasshi (2008) 0.91
Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol (2006) 0.91
Local interferon-alpha gene therapy elicits systemic immunity in a syngeneic pancreatic cancer model in hamster. Cancer Sci (2007) 0.89
New genetic causes of pheochromocytoma: current concepts and the clinical relevance. Keio J Med (2005) 0.88
Serum level of macrophage colony-stimulating factor is increased in prostate cancer patients with bone metastasis. Hum Cell (2008) 0.88
Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer. Int J Urol (2010) 0.87
A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells. J Urol (2007) 0.86
Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience. Int J Urol (2010) 0.85
Detection of circulating MUC7-positive cells by reverse transcription-polymerase chain reaction in bladder cancer patients. Int J Urol (2004) 0.84
Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. Hum Gene Ther (2007) 0.84
Value of reverse transcription polymerase chain assay in peripheral blood of patients with urothelial cancer. J Urol (2004) 0.81
Oncological outcome of retroperitoneoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma. Int J Urol (2006) 0.80
Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer. Int J Urol (2009) 0.80
Expression of galectin-1, a new component of slit diaphragm, is altered in minimal change nephrotic syndrome. Lab Invest (2008) 0.79
Predictors of septic shock in obstructive acute pyelonephritis. World J Urol (2013) 0.79
Genotypes of autosomal dominant polycystic kidney disease in Japanese. J Hum Genet (2002) 0.79
Serum level and immunohistochemical expression of vascular endothelial growth factor for the prediction of postoperative recurrence in renal cell carcinoma. BMC Res Notes (2014) 0.78
Intratumoral interferon-alpha gene transfer enhances tumor immunity after allogeneic hematopoietic stem cell transplantation. Cancer Immunol Immunother (2008) 0.78
The effect of eicosapentaenoic acid on prostate-specific antigen. In Vivo (2006) 0.77
11beta-hydroxysteroid dehydrogenase type 2 is expressed in the human kidney glomerulus. J Clin Endocrinol Metab (2002) 0.77
[Predicting postoperative recurrence of renal cell carcinoma using serum vascular endothelial growth factor]. Nihon Hinyokika Gakkai Zasshi (2013) 0.76
Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor. J Urol (2005) 0.76
A pilot study of quality of life of patients with hormone-refractory prostate cancer after gene therapy. Anticancer Res (2009) 0.75
[Case of congenital bladder diverticulum--cause of urinary retention in adulthood]. Nihon Hinyokika Gakkai Zasshi (2010) 0.75
Comparison of transperitoneal and retroperitoneal laparoscopic nephrectomy for renal cell carcinoma: a single-center experience of 100 cases. Int J Urol (2008) 0.75
Retroperitoneal laparoscopic single-site nephroureterectomy: Initial operative experience. Asian J Endosc Surg (2012) 0.75
[Polycystic kidney disease]. Nihon Jinzo Gakkai Shi (2007) 0.75
[Urolithiasis in hemodialysis patients]. Nihon Rinsho (2004) 0.75
Detection of mucin 7 gene expression in exfoliated cells in urine from patients with bladder tumor. Urology (2003) 0.75
[Urachal anomalies and tumor: clinical investigation of 14 cases]. Hinyokika Kiyo (2005) 0.75
[A case of post-traumatic high flow priapism]. Nihon Hinyokika Gakkai Zasshi (2003) 0.75
Stimulation of virus-specific T cell responses by dendritic cell vaccination in the chronic phase of simian AIDS models. Jpn J Infect Dis (2004) 0.75
[Prevalence and preference with regard to various surgical treatments for benign prostatic hypertrophy: a survey for the Japanese endourology and ESWL society member]. Nihon Hinyokika Gakkai Zasshi (2003) 0.75
Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL. Int J Urol (2003) 0.75